Diabetes, cognitive impairment, and dementia
- PMID: 18174567
- PMCID: PMC2174783
- DOI: 10.1136/bmj.39386.664016.BE
Diabetes, cognitive impairment, and dementia
Abstract
Are strongly linked, but the precise mechanisms are unclear
Conflict of interest statement
Competing interests: All authors are grant holders for the ET2DS, a substudy of which is supported by Pfizer. MWJS has received consultancy fees, fees for speaking, and reimbursement for attending a symposium from GlaxoSmithKline (GSK), manufacturers of rosiglitazone. MWJS also sits on a GSK independent data monitoring committee. MWJS has received funds to support staff members from other companies that make drugs for diabetes—Takeda, Pfizer, and Sanofi Aventis. JFP has received research funding from Bayer Healthcare. BMF has received research funding, consultancy fees, and honorariums for lectures from Eli Lilly, Takeda, GSK, Sanofi-Aventis, and Novo Nordisk.
References
-
- Personal Social Services Research Unit. Dementia UK. 2007. www.alzheimers.org.uk/News_and_Campaigns/Campaigning/PDF/Dementia_UK_Ful...
-
- Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes: a systematic review. Lancet Neurol 2006;5:64-74. - PubMed
-
- Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. Diabetologia 2005;48:2460-9. - PubMed
-
- Strachan MWJ, Deary IJ, Ewing FME, Frier BM. Is type 2 (non-insulin dependent) diabetes mellitus associated with a decline in cognitive function? A critical review of published studies. Diabetes Care 1997;20:438-45. - PubMed